Business Context and Reporting Period
This Form 8-K reports the September 24, 2021 closing of the business combination between Rotor Acquisition Corp. and Sarcos Corp. Rotor changed its name to Sarcos Technology and Robotics Corporation. Sarcos became the surviving operating business and ceased to be a shell company. The filing is not a Palladyne AI Corp. filing; the provided text identifies the registrant as Sarcos Technology and Robotics Corporation.
Sarcos develops mobile, dexterous robotic systems for industrial and defense applications. Its commercially available product at the time was Guardian S; Guardian XO and Guardian XT were still under development.
Key Financial Metrics
| Metric | Six months ended June 30, 2021 | Six months ended June 30, 2020 | Change |
|---|---|---|---|
| Revenue | $2.942 million | $3.882 million | Down 24% |
| Operating loss | $12.859 million | $10.244 million | Loss increased $2.615 million |
| Net loss | $10.461 million | $10.156 million | Loss increased $0.305 million |
| Research and development expense | $6.869 million | $6.642 million | Up 3% |
| General and administrative expense | $5.235 million | $3.706 million | Up 41% |
| Sales and marketing expense | $1.819 million | $1.285 million | Up 42% |
| Net cash used in operating activities | $13.660 million | $7.605 million | Use increased 80% |
| Net cash used in investing activities | $2.282 million | $0.342 million | Use increased $1.940 million |
As of June 30, 2021, Old Sarcos had $19.540 million of cash and cash equivalents, $30.574 million of total assets, and $7.919 million of total liabilities. On a pro forma basis assuming the business combination and PIPE financing, cash and cash equivalents would have been approximately $252.2 million as of June 30, 2021.
The company reported no clear post-closing debt balance in the provided text. It received $220 million in gross PIPE proceeds and stated that available cash following the transaction was expected to fund operating and capital requirements for at least 12 months from the filing date.
Material Changes Versus Prior Comparable Period
- Revenue declined 24% for the first six months of 2021, primarily because completed or winding-down research and development projects were not fully offset by newer projects and because Guardian S product sales declined.
- Operating expenses increased 12%, led by higher general and administrative costs associated with audit, professional services, facilities, recruiting and public-company preparation.
- Operating cash usage increased to $13.7 million from $7.6 million, while investing cash usage increased primarily because of tenant improvements, furniture and equipment for a new facility.
- A $2.394 million gain from forgiveness of a first-draw Paycheck Protection Program loan reduced the reported net loss for the six months ended June 30, 2021.
- The company completed a merger, issued 110,192,507 shares to former Old Sarcos equity holders and issued 22,000,000 PIPE shares at $10 per share.
- Following closing, approximately 142,718,497 common shares and 20,549,468 warrants were outstanding, in addition to 8,701,011 shares subject to options, 5,129,222 shares subject to restricted stock awards and 1,106,384 shares subject to restricted stock units.
Transaction, Capital Structure and Governance
- Each Old Sarcos common share converted at an exchange ratio of approximately 5.129222424 shares of the new company, subject to rounding and contingent consideration.
- Potential earn-out consideration consists of 14,062,500 shares if the stock price reaches $15 for the specified trading-period condition and another 14,062,500 shares if it reaches $20 for the specified condition.
- Common stock and warrants began trading on Nasdaq under STRC and STRCW on September 27, 2021.
- Public warrants have an $11.50 exercise price, become exercisable beginning January 20, 2022 subject to stated conditions, and expire September 24, 2026 unless earlier redeemed or otherwise terminated.
- The company adopted amended and restated charter and bylaws, a 2021 equity incentive plan, an employee stock purchase plan, registration rights arrangements and lock-up agreements.
- Ernst & Young LLP replaced Marcum LLP as independent registered public accounting firm. The filing notes a pre-transaction material weakness related to accounting for warrants, but no disagreements or other reportable events with Marcum.
Guidance, Outlook, Risks and Unusual Items
- Management expected beta Guardian XO and Guardian XT units to be available for customer pilots in the first half of 2022 and commercial availability by the end of 2022, while warning that the timeline could be delayed.
- The planned business model for Guardian XO and Guardian XT is primarily Robots-as-a-Service. The filing cited anticipated starting prices of approximately $9,000 per month per Guardian XO unit and $5,000 per month per Guardian XT unit, excluding the Guardian XT base.
- The company had no RaaS subscription agreements as of the filing date, and demand for the new robotic product category remained unproven.
- Key risks include development and manufacturing delays, component and supply-chain constraints, recruitment challenges, uncertain customer adoption, increased expenses, the need for additional capital, competition, intellectual-property protection, regulatory changes and COVID-19 impacts.
- Management expected research and development, capital expenditures, sales and marketing, infrastructure and public-company costs to increase significantly.
- The filing states that COVID-19 had adversely affected testing, customer activity, recruiting and travel, although it could also increase interest in robotic systems that reduce workplace exposure.
Investor Verification Points
- Verify the registrant identity and ticker: the supplied filing is for Sarcos Technology and Robotics Corporation, not Palladyne AI Corp.
- Review the unaudited pro forma financial statements to determine the post-combination capitalization, cash balance, transaction costs and accounting treatment of the merger and warrants.
- Reconcile the stated approximately $252.2 million pro forma cash balance with PIPE proceeds, redemption activity and transaction expenses.
- Assess cash burn and funding needs against management’s statement that liquidity would support at least 12 months of operations.
- Track commercialization milestones for Guardian XO and Guardian XT, including beta pilots, manufacturing readiness and customer commitments.
- Evaluate dilution from the 20.5 million warrants, 8.7 million options, restricted awards and potential 28.125 million earn-out shares.
- Review the warrant registration requirements, redemption provisions and the disclosed material weakness concerning warrant accounting.